LONDON, Nov 23 (Reuters) - Britain's AstraZeneca said on
Monday its vaccine for the novel coronavirus could be around 90%
effective without any serious side effects, the latest drugmaker
to unveil positive interim data in a scientific race to curb a
global pandemic.
Below are highlights from a press conference given by
AstraZeneca and Oxford University following the release of the
trial results of their vaccine.
MENE PANGALOS, ASTRAZENECA'S EXECUTIVE VICE PRESIDENT OF
BIOPHARMACEUTICALS R&D
"Both dose regimens are well tolerated... and the half dose
+ full dose is even better tolerated."
PASCAL SORIOT, CEO OF ASTRAZENECA
"Being able to vaccinate more people faster is a really a
big plus."
ANDREW POLLARD, DIRECTOR OF THE OXFORD VACCINE GROUP
"This means we have a vaccine for the world.
"It prevents severe disease and hospitalisation.
"This is an incredibly exciting moment for human health."
(Reporting by Kate Kelland)